Table 1.

Principal miRNAs involved in drug resistance (DR) of hematological tumor.

Hematological Tumor	miRNA	Drug Resistance	Cell Type	Pathway	Ref.
Chronic myeloid leukemia (CML)	miR-1228 miR-1246 miR-1308 miR-149 miR-455-3p miR-365 miR-27a miR-451 miR-21	Imatinib Imatinib Imatinib Imatinib Imatinib Imatinib Resistance phenotype Resistance phenotype Resistance phenotype	CEM CEM CEM CEM CEM CML CML CML CML	Exosome increaseExosome increase Exosome increase Exosome increase Exosome increase Bax-Caspase3 P-gp P-gp P-gp	[169] [169] [169] [169] [169] [170] [171] [171] [171]
Acute myeloid leukemia (AML)	miR-7977 miR-19b miR-20a	Anthracyclines Anthracyclines Anthracyclines	HL-60/AR HL-60/AR HL-60/AR	P-gp PTEN and P-gp PTEN and P-gp	[172] [173] [173]
Chronic lymphocytic leukemia (CLL)	miR-146a	Resistance phenotype	CCL	Akt-NF-kB	[173]
Lymphoma	miR-181a miR-548m miR-99a-5p miR-125b-5p	Resistance phenotype Resistance phenotype Resistance phenotype Resistance phenotype	NHL NHL DLBCL DLBCL	Bim c-Myc-HDAC6 Exosome increase Exosome increase	[174] [175] [176] [176]
Multiple myeloma	miR-627-3p miR-642a-5p miR-16-5p miR-15a-5p miR-20a-5p miR17-5 miR-30	Bortezomib Bortezomib Bortezomib Bortezomib Bortezomib Bortezomib Resistance phenotype	LP-1 myeloma cells LP-1 myeloma cells U-226 myeloma cell U-226 myeloma cell U-226 myeloma cell U-226 myeloma cell H929 myeloma cell	SP9-PI3K/Akt SP9-PI3K/Akt Exosome increase Exosome increase Exosome increase Exosome increase BCL9-Wnt	[40] [40] [43] [43] [43] [43] [177]